-
00:23
1.
index 1
-
01:16
2.
Title
-
01:36
3.
About Breast Cancer
-
00:52
4.
Triple Negative Breast Cancer Subtype
-
01:06
5.
FUSCC TNBC Subtype
-
01:05
6.
FUSCC TNBC Subtype
-
01:00
7.
Luminal Androgen Receptor LAR
-
00:47
8.
Immunomodulatory IM
-
01:12
9.
Basal-like Immune-suppressed BLIS
-
00:51
10.
Mesenchymal-like MES
-
00:49
11.
FUTURE clinical trial
-
00:43
12.
Slide 12
-
01:38
13.
Metabolic Dysregulation in TNBCs
-
00:55
14.
Estimation of the Optimal Clustering Numbers of TNBC Subtypes
-
01:10
15.
Metabolic-Pathway-Based Stratification of TNBC
-
01:20
16.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:32
17.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
01:04
18.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
01:23
19.
Slide 20
-
00:51
20.
The Metabolomic Landscape of TNBC
-
01:37
21.
Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
-
01:18
22.
NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
-
01:05
23.
NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
-
00:34
24.
Slide 26
-
00:55
25.
Ferroptosis
-
00:48
26.
Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
-
01:02
27.
Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
-
00:36
28.
Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
-
01:16
29.
Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
-
01:02
30.
Multiple Ferroptosis Inducers Highlights the Importance of GPX4 in LAR Tumors
-
00:34
31.
Multiple Ferroptosis Inducers Highlights the Importance of GPX4 in LAR Tumors
-
00:57
32.
AR is the key regulator of GPX4 expression in LAR tumors
-
01:09
33.
AR is the key regulator of GPX4 expression in LAR tumors
-
00:39
34.
AR Binds to the GPX4 Promoter and Drives its Expression
-
01:19
35.
Targeting GPX4 is a Better Strategy than Targeting AR for Patients
-
01:36
36.
Targeting GPX4 is a Better Strategy than Targeting AR for Patients
-
01:19
37.
GPX4 Inhibitors Diminish Tumor Growth In Vivo
-
00:59
38.
Slide 40
-
00:53
39.
Slide 41
-
04:54
40.
Slide 40
-
00:10
41.
Polar Metabolite and Lipid Profiling of TNBC
-
00:37
42.
The Metabolomic Landscape of TNBC
-
01:10
43.
Metabolic-Pathway-Based Stratification of TNBC
-
03:22
44.
Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
-
00:17
45.
Glutathione metabolism is essential for suppressing ferroptosis in LAR tumors
-
00:01
46.
Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
-
00:00
47.
Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
-
00:00
48.
Ferroptosis
-
00:00
49.
Slide 26
-
04:28
50.
Ferroptosis
-
00:36
51.
About Breast Cancer
-
00:02
52.
** after 1112seminar.pptx
-
00:01
53.
About Breast Cancer
-
00:00
54.
Triple Negative Breast Cancer Subtype
-
00:00
55.
FUSCC TNBC Subtype
-
00:00
56.
FUSCC TNBC Subtype
-
00:00
57.
Luminal Androgen Receptor LAR
-
00:01
58.
Immunomodulatory IM
-
00:00
59.
Basal-like Immune-suppressed BLIS
-
00:00
60.
Mesenchymal-like MES
-
00:00
61.
Basal-like Immune-suppressed BLIS
-
00:03
62.
Immunomodulatory IM
-
00:00
63.
Luminal Androgen Receptor LAR
-
00:00
64.
FUSCC TNBC Subtype
-
00:00
65.
Luminal Androgen Receptor LAR
-
00:00
66.
Immunomodulatory IM
-
00:00
67.
Basal-like Immune-suppressed BLIS
-
00:00
68.
Mesenchymal-like MES
-
00:00
69.
Basal-like Immune-suppressed BLIS
-
00:00
70.
Immunomodulatory IM
-
00:39
71.
Luminal Androgen Receptor LAR
-
00:01
72.
Immunomodulatory IM
-
00:00
73.
Basal-like Immune-suppressed BLIS
-
00:01
74.
Mesenchymal-like MES
-
00:01
75.
FUTURE clinical trial
-
00:01
76.
Slide 12
-
00:02
77.
Metabolic Dysregulation in TNBCs
-
00:07
78.
Estimation of the Optimal Clustering Numbers of TNBC Subtypes
-
00:03
79.
Metabolic Dysregulation in TNBCs
-
00:47
80.
About Breast Cancer
-
00:00
81.
Triple Negative Breast Cancer Subtype
-
00:23
82.
FUSCC TNBC Subtype
-
00:00
83.
FUSCC TNBC Subtype
-
00:00
84.
Luminal Androgen Receptor LAR
-
00:00
85.
Immunomodulatory IM
-
00:00
86.
Basal-like Immune-suppressed BLIS
-
00:00
87.
Mesenchymal-like MES
-
02:10
88.
FUTURE clinical trial
-
00:07
89.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:01
90.
Metabolic-Pathway-Based Stratification of TNBC
-
00:06
91.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:04
92.
Metabolic-Pathway-Based Stratification of TNBC
-
02:30
93.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:02
94.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:57
95.
The Metabolomic Landscape of TNBC
-
00:01
96.
Slide 20
-
00:04
97.
The Metabolomic Landscape of TNBC
-
00:02
98.
Slide 20
-
00:27
99.
Polar Metabolite and Lipid Profiling of TNBC
-
00:01
100.
The Metabolomic Landscape of TNBC
-
00:00
101.
Polar Metabolite and Lipid Profiling of TNBC
-
00:00
102.
The Metabolomic Landscape of TNBC
-
00:07
103.
Polar Metabolite and Lipid Profiling of TNBC
-
00:00
104.
The Metabolomic Landscape of TNBC
-
00:06
105.
Polar Metabolite and Lipid Profiling of TNBC
-
00:09
106.
The Metabolomic Landscape of TNBC
-
00:00
107.
Polar Metabolite and Lipid Profiling of TNBC
-
00:00
108.
Slide 20
-
00:00
109.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:00
110.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:00
111.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:16
112.
Metabolic-Pathway-Based Stratification of TNBC
-
00:08
113.
Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
-
00:27
114.
Metabolic-Pathway-Based Stratification of TNBC
-
00:00
115.
Estimation of the Optimal Clustering Numbers of TNBC Subtypes
-
00:00
116.
Metabolic Dysregulation in TNBCs
-
00:00
117.
Slide 12
-
00:00
118.
FUTURE clinical trial
-
00:16
119.
Slide 12
-
00:00
120.
Metabolic Dysregulation in TNBCs
-
00:00
121.
Estimation of the Optimal Clustering Numbers of TNBC Subtypes
-
00:59
122.
Metabolic-Pathway-Based Stratification of TNBC
-
01:42
123.
NAAG is a Crucial Tumor-Promoting Metabolite in BLIS
-
00:07
124.
Targeting GPX4 is a Better Strategy than Targeting AR for Patients
-
00:01
125.
AR Binds to the GPX4 Promoter and Drives its Expression
-
00:15
126.
AR is the key regulator of GPX4 expression in LAR tumors
-
00:01
127.
AR Binds to the GPX4 Promoter and Drives its Expression
-
00:00
128.
Targeting GPX4 is a Better Strategy than Targeting AR for Patients
-
01:58
129.
Targeting GPX4 is a Better Strategy than Targeting AR for Patients
-
01:05
130.
Slide 40
-
01:57
131.
Metabolomic Subtyping Refines the Transcriptomic Subtyping in BLIS
-
00:07
132.
FUSCC TNBC Subtype
-
00:00
133.
Luminal Androgen Receptor LAR
-
00:01
134.
Immunomodulatory IM
-
00:00
135.
Basal-like Immune-suppressed BLIS
-
00:01
136.
Mesenchymal-like MES
-
00:28
137.
FUTURE clinical trial
-
00:00
138.
Mesenchymal-like MES
-
00:00
139.
Basal-like Immune-suppressed BLIS
-
00:00
140.
Immunomodulatory IM
-
00:00
141.
Luminal Androgen Receptor LAR
-
00:00
142.
FUSCC TNBC Subtype
-
00:00
143.
FUSCC TNBC Subtype
-
00:00
144.
Triple Negative Breast Cancer Subtype
-
00:01
145.
About Breast Cancer
-
00:18
146.
Title
-
00:10
147.
About Breast Cancer
-
00:01
148.
Triple Negative Breast Cancer Subtype
-
00:02
149.
FUSCC TNBC Subtype
-
00:48
150.
Triple Negative Breast Cancer Subtype
-
00:55
151.
FUSCC TNBC Subtype
-
00:28
152.
FUSCC TNBC Subtype
-
00:24
153.
Luminal Androgen Receptor LAR
-
00:00
154.
Immunomodulatory IM
-
00:36
155.
Basal-like Immune-suppressed BLIS
-
00:23
156.
Mesenchymal-like MES
-
00:18
157.
FUTURE clinical trial
-
00:35
158.
Slide 12
-
00:00
159.
Metabolic Dysregulation in TNBCs
-
00:00
160.
Estimation of the Optimal Clustering Numbers of TNBC Subtypes
-
00:31
161.
Metabolic-Pathway-Based Stratification of TNBC
-
00:00
162.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:01
163.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:30
164.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:00
165.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:07
166.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:19
167.
Slide 20
-
00:01
168.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:00
169.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:00
170.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:00
171.
Metabolic-Pathway-Based Stratification of TNBC
-
01:46
172.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:01
173.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:05
174.
Metabolic Subtypes Sensitivity to Various Metabolic Inhibitors
-
00:05
175.
Slide 26
-
00:41
176.
Ferroptosis
-
00:33
177.
AR is the key regulator of GPX4 expression in LAR tumors
-
00:00
178.
AR Binds to the GPX4 Promoter and Drives its Expression
-
00:00
179.
Targeting GPX4 is a Better Strategy than Targeting AR for Patients
-
01:26
180.
Targeting GPX4 is a Better Strategy than Targeting AR for Patients
-
00:53
181.
Heterogeneity of ferroptosis-related characteristics in TNBC subtypes
-
05:46
182.
GPX4 Inhibitors Diminish Tumor Growth In Vivo
-
00:07
183.
** after 1112seminar.pptx